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Abstract
Acute myocardial infarction (AMI) is the leading cause of mortality worldwide. Major
advances  in  the treatment  have included coronary interventions,  such as  systemic
thrombolysis and percutaneous coronary angioplasty (PCA). These procedures have
been aimed to recover the blood flow in the cardiac zones affected by the occlusion of
a branch of the coronary artery. However, damage is generated in the heart tissue
known as myocardial reperfusion injury, an event associated with increased oxidative
stress.  Reactive oxygen species (ROS) are able to trigger cell  death pathways,  and
myocardial structural and functional impairment. Studies on animal models of AMI
suggest that lethal reperfusion accounts for up to 50% of the final size of a myocardial
infarct, a part of the damage likely to be prevented. Although a number of strategies
have been aimed to ameliorate lethal reperfusion injury, up to date the beneficial effects
in clinical settings remain elusive. The accumulated body of evidence suggests that
redox  balance  is  a  crucial  determinant  of  ischemia–reperfusion  injury,  with  clear
mechanistic  insights  into  pharmacological  approaches.  This  chapter  presents  the
molecular basis for a novel cardioprotection of patients with AMI subjected to PCA,
based on a reinforcement of the antioxidant system.
Keywords: acute myocardial infarction, ischemia–reperfusion, oxidative stress, anti‐
oxidant therapy, coronary angioplasty
1. Introduction
According to the World Health Organization, a total of 56 million deaths occurred worldwide
during 2012 and 17.5 million (31.25%) were due to cardiovascular diseases, still the principal
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cause of  death by noncommunicable diseases.  In addition,  deaths due to ischemic heart
disease (IHD) in 2012 were estimated as 7.4 million (13.2%), remaining as the leading cause
of death over the past decade [1,  2],  with a considerable social  impact due to mortality,
morbidity,  loss of  quality of  life  and high economic cost.  In IHD, severe and prolonged
myocardial  ischemic events occur through thrombotic complications from atherosclerotic
plaques in pericardial coronary arteries, leading to cardiomyocyte death. The latter becomes
more significant when ischemia is caused by complete coronary occlusion, generating an
acute  myocardial  infarction  (AMI)  where  the  coronary  microcirculation  is  significantly
reduced, affecting most of the left ventricular wall thickness together with structural and
functional impairments, scarring and adverse remodeling [3, 4]. The most effective therapeu‐
tic  intervention for  reducing the size of  a  myocardial  infarct  and improving the clinical
outcome is timely and effective restoring of coronary flow using either thrombolytic therapy
or percutaneous coronary angioplasty (PCA), but this process can itself induce further viable
cardiomyocyte  death  and  increased  infarct  size,  a  phenomenon  known  as  myocardial
reperfusion injury (MRI), thus reducing the beneficial effects. The MRI causes four types of
cardiac dysfunction, the first two being reversible and the others irreversible: (i) reperfusion‐
induced arrhythmias; (ii) myocardial stunning; (iii) microvascular obstruction or no‐reflow
phenomenon;  and  (iv)  lethal  myocardial  reperfusion  injury  (LMRI).  LMRI  is  the  most
important because may account for up to 50% of the myocardial infarct (MI) final size as
shown in both experimental ischemia–reperfusion (I/R) models and patients with ST‐segment
elevation MI applying therapeutic interventions solely at the onset of myocardial reperfusion
[5, 6]. In addition, several experimental studies have shown the important role of oxidative
stress in MRI and it has been postulated as a therapeutic target for cardioprotection [7–13].
However,  the clinical  trials  have shown mixed results  with no clear confirmation of  the
beneficial effects of exogenous antioxidant therapy at the onset of myocardial revasculariza‐
tion, possibly due to differences in the design and methodology [14]. Next, we describe the
pathophysiological  mechanisms  involved  in  MRI  and  the  molecular  basis  for  a  novel
cardioprotective treatment of patients with AMI subjected to PCA, based on a reinforcement
of the antioxidant system.
2. Oxidative stress and the pathophysiology of myocardial ischemia–
reperfusion injury
Occlusion of a coronary artery decreases blood flow to myocardial tissue causing a state of
prolonged ischemia. The lack of oxygen and nutrients triggers a series of abrupt metabolic and
biochemical changes within the cardiomyocyte that lead to several mechanisms of cell death,
which are enhanced in the reperfusion (Figure 1).
During acute myocardial ischemia, the absence of oxygen in the mitochondrial electron
transport chain (mETC) causes a drop in the production of adenosine triphosphate (ATP), and
the glycolytic pathway generates a shift to anaerobic respiration with intracellular accumula‐
tion of lactic acid [9, 15]. In addition, the Krebs cycle stops and CO2 cannot be eliminated from
the extracellular space due to blood flow arrest. Therefore, a decrease in the intracellular pH
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(<7.0) occurs, which increases the Na+ influx through the Na+/H+ exchanger, while the ATP
depletion stops Na+ efflux through Na+/K+‐ATPase. This intracellular Na+ accumulation
activates Na+/Ca2+ exchangers in the reverse direction leading to cytosolic Ca2+ overload [16],
where the sarcoplasmic reticulum is unable of uptaking Ca2+ from the cytosol because
sarco(endo)plasmic reticulum Ca2+‐ATPase (SERCA) transporter needs ATP to function [17].
High levels of intracellular Ca2+ induce the conversion, via limited proteolysis and sulfhydryl
oxidation, of xanthine dehydrogenase to xanthine oxidase (XO) in endothelial cells mainly, an
isoform that produces superoxide anion and hydrogen peroxide (H2O2) from oxygen [18]. The
acidic conditions exert a strong inhibitory effect on the mitochondrial permeability transition
pore (mPTP) [19], despite the presence of inducing factors opening such as Ca2+ and inorganic
phosphate overload, oxidative stress and ADP. The mPTP is an inner mitochondrial membrane
protein channel that, when it is open under certain conditions, mediates non‐selective
permeability to molecules less than 1.5 kDa, collapsing the mitochondrial membrane potential
and uncoupling oxidative phosphorylation, leading to ATP depletion, mitochondrial matrix
swelling and cell death through apoptosis and necrosis [20]. In addition, acidosis and low levels
of ATP reduces the myocardial contractile activity [21].
The coronary revascularization postmyocardial ischemia rapidly increases the level of tissue
oxygenation, which triggers a series of mechanisms producing LMRI. The most important
mediators of this process are described below.
2.1. Oxidative stress
During the first minutes of the onset of myocardial reperfusion, a burst of ROS occurs, in
accordance with several experiments demonstrating direct measurements of free radicals in
isolated hearts and in vivo I/R models [8, 10–13]. The potential enzymatic sources of ROS
production in cardiac tissue exposed to I/R are xanthine oxidase (XO) in endothelial cells,
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) in neutrophils,
mETC, uncoupled nitric oxide synthase (uncNOS), cytochrome P450, lipoxygenase/cyclooxy‐
genase and monoamine oxidase [22]. XO activation and ATP catabolism to hypoxanthine occur
in ischemic period, generating high levels of ROS together with uric acid from oxygen and
accumulated hypoxanthine (or xanthine), when blood flow is restored [18]. The important role
of NOX family in the MRI has been shown in experimental studies where NOX‐isoform‐
specific knockout mice have significantly reduced infarct sizes compared to wild‐type (WT)
controls, confirming these results in buffer‐perfused Langendorff models [23]. Cardiolipin
peroxidation and cytochrome oxidase uncoupling in ischemic period results in the inhibition
of electron flux through mETC, ATP depletion and increased superoxide anion generation, a
situation that persists in the reperfusion where the Krebs cycle is reactivated and high levels
of tissue oxygen can lead to increased ROS production [24]. Tetrahydrobiopterin (BH4), a NOS
cofactor, suffers oxidation to dihydrobiopterin in prolonged ischemia, resulting in loss of NOS
enzyme affinity by the substrate l‐citrulline together with a shift in the generation of nitric
oxide (NO), a potent vasodilator, to superoxide anion during reperfusion [24, 25].
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Figure 1. Schematic representation of the pathophysiological mechanism involved in myocardial damage due to I/R.
ATP, adenosine triphosphate; mPTP, mitochondrial permeability transition pore; NOX, NADPH oxidase; NF‐κB, nucle‐
ar factor kappa B; Nrf2, nuclear factor‐erythroid 2‐related factor 2; ROS, reactive oxygen species; uncNOS, uncoupled
nitric oxide synthase; XO, xanthine oxidase; Ca2+, calcium; DNA, deoxyribonucleic acid.
Exacerbation of oxidative stress during postischemia myocardial reperfusion overwhelms the
endogenous antioxidant defenses, causing free radical propagation reactions with direct
damage to cellular biomolecules as lipid peroxidation, protein oxidation/nitration and DNA
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damage [24, 26]. The main effecter of ROS‐induced damage is the highly reactive hydroxyl
radical generated from Fenton/Haber–Weiss reactions and peroxynitrite (reviewed in Section
3) [24], demonstrating its formation in a postischemia reperfused heart [11]. In addition, ROS
can induce activation both of nuclear factor kappa B (NF‐κB) and nuclear factor‐erythroid 2‐
related factor 2 (Nrf2)‐signaling pathways, although the ROS concentration threshold has not
been experimentally determined [27]. NF‐κB proteins are a family of transcription factors with
a central role in regulating the expression of genes related with inflammation, immune
response, cell proliferation and apoptosis [28–30], and different levels of ROS can both activate
and inhibit NF‐κB‐signaling, depending on the context, with a high degree of complexity [31].
On the other hand, Nrf2 is a transcription factor that positively regulates the human antioxi‐
dant response element (ARE), leading to the gene expression of endogenous antioxidant
defence system. Kelch‐like ECH‐associated protein 1 (Keap1) is a suppressor protein anchored
in the cytoplasm that physically binds Nrf2, but oxidative stress facilitates the complex
dissociation and Nrf2 nuclear translocation to ARE‐containing promoters [32]. A study
demonstrated that Nrf2 is indispensable for the regulation of both constitutive and inducible
expression of antioxidants and phase‐2 enzymes in mouse primary cardiomyocytes [33]. In
clinical trials, the antioxidant therapy at the onset of reperfusion, in patients with AMI
subjected to PCA, has mainly considered the use, alone or combined, of ROS scavengers,
inhibitors of ROS sources, human recombinant antioxidant enzymes and reduced glutathione
donor [14].
2.2. Intracellular pH
The intracellular acidic pH generated in ischemia returns to physiological values during
myocardial reperfusion [9]. Bond et al. [34] simulated I/R conditions in cultured neonatal rat
cardiac myocytes, demonstrating that when intracellular acidic pH increases to 7.4 hypercon‐
tracture and cell death occur. In addition, free Ca2+ increases during simulated ischemia and
in simulated reperfusion. Under conditions of ischemia, it was shown in cultured cardiac
myocytes and perfused papillary muscles that inhibition of Na+/H+ exchanger delayed the
increase of intracellular pH after reperfusion and prevented reperfusion‐induced cell killing,
but not reduce the increase in intracellular‐free Ca2+ [35]. By contrast, reperfusion with
inhibition of Na+/Ca2+ exchanger decreases intracellular free Ca2+ but did not reduce cell killing.
These results suggest that acidotic pH is generally protective in I/R, and Na+/H+ exchanger
contributes to reperfusion washout effect on intracellular acidic pH, leading to a Ca2+‐inde‐
pendent lethal reperfusion injury in cardiomyocytes.
2.3. The mPTP opening
Recently, it has been proposed that various potential protein components either to form the
molecular structure of the mPTP or to regulate its opening [20, 36]. It was shown that the mPTP
opening occurs within the first few minutes postischemia myocardial reperfusion [37], with
both burst of oxidative stress and intracellular pH normalization (possibly due to the inhibitory
effect of acid pH on mPTP is removed) as the main contributing factors [38, 39]. On the other
hand, Ca2+ overload seems not to be a causative factor in I/R model. In adult rat myocytes, both
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cytosolic and mitochondrial Ca2+ increased during ischemia but decreases to basal levels in the
first minutes of reperfusion. Ca2+ overload occurred late in both compartments, event that was
prevented by mPTP inhibitors. Besides, intramitochondrial Ca2+ chelation did not prevent cell
death after reperfusion. Thus, Ca2+ overload appears to be the consequence of bioenergetic
failure after mPTP opening [38]. Another study showed that, at the onset of reperfusion, there
is a transient increase in cytosolic Ca2+ levels together with a simultaneous transient sarco‐
plasmic reticulum Ca2+ depletion [40], corroborating the latter. The mPTP is a potential
pharmacological target for prevent LMRI, and experimental studies with mPTP inhibitors
(such as cyplosporin A), at the onset of myocardial reperfusion, has been reported to reduce
MI size by 40–50% [41–44].
2.4. Inflammation
Ischemia is associated with slow infiltration of neutrophils, but recruitment toward the necrotic
zone is favored after reperfusion by increased ROS exacerbation that triggers upregulation of
adhesion molecules (P‐selectin, CD11/CD18, ICAM‐1) in cardiomyocytes, with cytokines
(TNFα, IL‐1, IL‐6, IL‐8, NAP‐1, PAF, MIP‐2) and complement, which are released from
ischemic‐reperfused myocardium. Neutrophils adhesion to coronary vascular endothelium
occurs rapidly (within minutes) after onset of reperfusion, with abundant accumulation into
the infarct zone during the following 6 hours. Neutrophils release more than 20 different
proteolytic enzymes (hydrolases, metalloproteinases, and proteases) and are a major ROS
source by generating superoxide anions through NOX, positioning them as important
contributors to MRI [45].
3. Cardioprotection by combined antioxidant therapy
After reviewing the most relevant pathophysiological processes of myocardial ischemia–
reperfusion injury, the central role being played by the burst of oxidative stress in the first
minutes of revascularization certainly has positioned itself as a pharmacological target of
choice. In the following section, we describe the molecular basis of an innovative combined
antioxidant therapy, which includes a reinforcement of endogenous antioxidant defences,
aimed to prevent or at least ameliorate the MRI in patients with AMI undergoing PCA.
3.1. Ascorbate
Vitamin C (ascorbic acid or ascorbate) is a potent water‐soluble antioxidant in humans, which
cannot be endogenously synthesized [46] and must be incorporated through vegetables and
fruits [47]. Vitamin C is an electron donor and is oxidized to dehydroascorbate when acting as
a reducing agent, returning to reduced form when is used by the cell [48] (Figure 2). A study
in a group of apparently healthy adult nonsmoking population showed an inverse correlation
between plasma vitamin C and products of oxidative damage to DNA, proteins and lipids [49].
Another study evaluated oxidant and antioxidant parameters in the blood of the patients with
MI before and after thrombolysis and showed that the activity of superoxide dismutase (SOD),
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an antioxidant enzyme, was significantly reduced, whereas the activity of XO, an oxidant
enzyme, together with the levels of malondialdehyde (MDA), a lipid peroxidation biomarker,
significantly increased after reperfusion. These parameters improved to normal or near‐
normal levels when patients were supplemented with oral vitamin C postreperfusion [50],
confirming the in vivo antioxidant capacity of vitamin C. Other properties of this compound
are described in the following experiments. Ascorbic acid, together vitamin E, reverse
endothelial dysfunction through a modulator effect by upregulating endothelial NOS (eNOS)
and downregulating NOX on the vascular wall [51]. In essential hypertensive patients,
impaired endothelium‐dependent vasodilation improved with vitamin C supplementation,
an effect that can be reversed by a NOS inhibitor, suggesting a restoration of NO availability
and oxidative stress‐mediated endothelium impairment in this pathology [52]. Pretreatment
with vitamin C prevents vascular function damage and release of IL‐6 induced by endothelin‐1
in humans [53]. Intracellular vitamin C in human cell lines and primary endothelial cells,
together with cell cultures in medium with dehydroascorbic acid, showed significantly
decreased TNFα‐induced NF‐κB activation [54].
Figure 2. Oxidation of ascorbate (AscH‾) to dehydroascorbic acid (Asc) for the loss of two electrons in succession,
through the formation of ascorbyl radical intermediate (Asc•‾). Importantly, ascorbate is the ionized form of ascorbic
acid (AscH2) at physiological pH (7.4).
Vitamin C has been used in I/R models. Gao et al. [55] demonstrated that in isolated rat hearts
subjected to I/R, glutathione monoethyl ester (GSHme), but no ascorbic acid, administered at
the onset of reperfusion exerted protective effects against MRI. Furthermore, GSHme coad‐
ministered together with ascorbic acid had enhanced protective effects, suggesting a syner‐
gistic effect between the two compounds. Another in vivo experimental study showed that
intravenous (IV) administration of vitamin C or vitamin C plus vitamin E, prior to coronary
occlusion following reperfusion, had not significant differences in infarct size compared to the
control group. Besides, vitamin C alone tends to increase infarct size, whereas the vitamin
combination tends to decrease [56]. The clinical trials in which vitamin C is orally administered,
in combination with other vitamins, in different doses to patients with cardiovascular history
showed no beneficial cardioprotective long‐term effects [27]. In patients with AMI subjected
to PCA, administration of vitamin C orally (2.0 g) followed by a constant infusion (20 mg/min),
before reperfusion, did not suppress the rapid and transient increase in levels of urinary 8‐epi‐
prostaglandin F2α (8‐epi‐PGF2α), a biomarker of oxidative stress in vivo, after PCA [57]. A
review [14] of the cardioprotective strategies using vitamin C in combination with other
vitamins in AMI followed by restoration of coronary blood flow showed variable results when
administered orally, but when an infusion of vitamin C (1000 mg/12 h) was followed by oral
doses (1200 mg/24 h) and vitamin E (600 mg/24 h), positive clinical outcomes were obtained
Novel Antioxidant Therapy Against Myocardial Ischemia–Reperfusion Injury During Percutaneous Coronary...
http://dx.doi.org/10.5772/63658
389
within a composite endpoint. According to the latter, a study in patients undergoing elective
percutaneous coronary intervention for stable angina showed that 1 g vitamin C administered
by infusion (16.6 mg/min), 1 hour before of intervention, improved the impaired microcircu‐
latory reperfusion and had significantly reduced plasma levels of oxidative stress biomarkers
[58].
These results could be explained by the fact that oral administration of vitamin C shows a
plasma concentration–time profile, in a dose range of 200–2500 mg/day, producing a steady‐
state plasma concentration approximately by 80 µmol/l (0.08 mmol/l), due to apparent
saturation of tissue uptake and in less degree by function of oral bioavailability and renal
excretion [59]. At these physiological concentrations, superoxide anion reacts with NO at a
rate 104‐fold greater than that at which it reacts with ascorbic acid (Table 1A and C), situation
that is favored during the ROS burst in the first minutes of postischemia myocardial reperfu‐
sion because superoxide anion levels are exacerbated.
Reaction Rate constant (M−1 s−1)
(A) O2· −+ ⋅ NO ONOO− 7 × 109
(B) O2· −+ SOD O2+ H2O2 2 × 109
(C) O2· −+ AscH2 Products 2.7–3.3 × 105
ONOO−, peroxynitrite; H2O2, hydrogen peroxide; O2, molecular oxygen [60–62].
Table 1. Comparison of the reaction rate constants of superoxide anion (O2•‾) with nitric oxide (•NO), superoxide
dismutase (SOD) and ascorbic acid (AscH2).
Superoxide anion reacts avidly with NO to form peroxynitrite (ONOO−) (Table 1A), an agent
very reactive and toxic to biomolecules, with a constant rate higher than that of the reaction
between superoxide anion and SOD (Table 1B). Furthermore, peroxynitrite (pKa at 37°C = 6.8)
can be protonated in medium with acidotic pH during ischemia, resulting in ONOOH that is
inherently unstable. Reperfusion restored the intracellular pH to physiologic levels, favoring
decomposition of ONOOH to hydroxyl radical and nitrogen dioxide radical (Figure 3) [24],
both responsible for generating oxidative stress and nitrosative stress damage to cardiomyo‐
cytes. Thus, peroxynitrite contributes to MRI generating lipid peroxidation and protein
nitration in tyrosine residues, affecting the function and structure of the latter; oxidation of
thiol groups related to cell antioxidant capacity; rupture of double‐stranded DNA; and BH4
NOS cofactor oxidation, which reduces the formation of NO [63].
Jackson et al. [64] demonstrated in vitro that supraphysiologic vitamin C concentration of 10
mmol/l is needed to overcome the competition with NO for superoxide. Consequently, only
IV infusion can achieve these plasma ascorbate levels. It has been documented that the use of
high doses of IV vitamin C over 10 mmol/l in patients appears to have a positive safety profile,
but it should be avoided in patients with renal function impairment or glucose‐6‐phosphate
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dehydrogenase deficiency [65]. Human plasma vitamin C concentration–time profile follow‐
ing short‐term IV infusion shows peak concentrations higher than 20 mmol/l, remaining over
10 mmol/l for 3 hours [66]. It is important to note that vitamin C needs to be incorporated into
the cell to exert its effects. Specific Na+‐dependent transporters for ascorbic acid (reduced form)
are called SVCT1 and SVCT2, while transporters for dehydroascorbic acid (oxidized form) are
members of GLUT family (GLUT1/3/4) that facilitate transport of glucose [67]. These trans‐
porters are expressed in the human myocardium [68–70].
Figure 3. Formation of hydroxyl radical (•OH) and nitrogen dioxide radical (NO2•) from peroxynitrite (ONOO‾)
through an intermediary peroxynitrous acid (ONOOH).
3.2. N-Acetyl cysteine
When ascorbate is oxidized to dehydroascorbate, it can return to its reduced form through a
reduced glutathione (GSH)‐dependent recycling mechanism inside the cell, which may be
direct [71] or enzyme mediated [72] (Figure 4) and can lead to a dehydroascorbate concentra‐
tion‐dependent decrease in intracellular GSH levels [71, 73, 74]. This process has been descri‐
bed in human erythrocytes [73], bovine aortic endothelial cells [74], among others and fulfills
a function of blood antioxidant reserve [75]. Glutathione (γ‐glutamyl‐cysteinyl‐glycine) is an
endogenous agent playing a primary role of nonenzymatic antioxidant defence together with
participating in metabolic processes and cellular regulation. It has a reduced form (GSH) and
an oxidized form (GSSG) which are interconvertible. It is synthesized in all cell types of the
organism, being mostly in the cytosol and to a lesser extent in the extracellular plasma [76].
Figure 4. Reduced glutathione (GSH)‐dependent reduction of dehydroascorbic acid (Asc), which may be mediated di‐
rectly or by enzyme. NADPH, nicotinamide adenine dinucleotide phosphate (reduced form); NADP+, nicotinamide ad‐
enine dinucleotide phosphate (oxidized form); GSSG, oxidized glutathione; AscH2, ascorbic acid; RH, unsaturated fatty
acid chain; R•, lipid alkyl radical.
If we consider an IV administration of high doses of vitamin C before, during and after PCA
in patients with AMI, the burst of ROS will be counteracted by ascorbic acid, which generates
large amounts of dehydroascorbic acid. We hypothesized that the latter interact with endog‐
enous GSH and will cause a drop in their levels, limiting the cardioprotective effect. For this
reason, we believe essential to reinforcement the endogenous antioxidant defence system with
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a GSH donor, such as N‐acetyl cysteine, to optimize antioxidant therapy. Furthermore, as
above‐mentioned, coadministration of a GSH donor and vitamin C tend to have a synergistic
protective effect on infarct size in an I/R model of isolated rat heart [56].
N‐Acetyl cysteine (NAC) is a drug currently used in clinic that has demonstrated a good safety
profile when administered orally, although adverse effects will be more noticeable at high
doses (>3 g/day) or IV administration (e.g., for the treatment of paracetamol overdose) [77]. In
experimental I/R models, high NAC dose administrated intracoronary with a radiographic
contrast in pigs, at the onset of reperfusion, was safe, reduced platelet reactivity and there was
a trend toward a better cardiac function at 24 h, but there was no significant difference in the
myocardial infarct size and did not provide significant renal protection compared to control
group [78]. On the other hand, in a rat I/R model, NAC administration by continuous infusion
before, during and after reperfusion produced a significant limitation of the infarct size
compared to control group, but injection of NAC bolus with the same total dose, before and
at onset of reperfusion, failed to reduce it [79]. In clinical trials, group of patients undergoing
coronary artery bypass and/or valve surgery treated with IV infusion of NAC, before and after
of surgery, decreases the incidence of postoperative atrial fibrillation compared to control
group [80]. LIPSIA‐N‐ACC trial [81], a randomized, single‐blind, controlled trial, was designed
to measure the effects of high doses of NAC on contrast‐induced nephropathy (CIN) and
reperfusion injury in ST‐segment elevation MI patients undergoing primary angioplasty
intervention (PCI) with moderate contrast volumes. CIN is the acute deterioration of renal
function occurring after intravascular administration of contrast media that is not attributable
to other causes, defined as increase in serum creatinine > 0.3 mg/dL or 25% above baseline
levels within 48 hours after contrast administration, which is associated with increased rates
of morbidity and mortality. Of the 251 patients enrolled, 126 were randomized to the NAC
treated group and 125 to the placebo group. NAC was administered as an IV bolus (1200 mg)
before angioplasty and twice daily for 48 hours after angioplasty. In addition, all patients and
controls were hydrated with IV infusion of NaCl (0.9%), at a rate of 1 ml/kg of body weight
per hour for 12 h, after PCI. Iopromide was used as a nonionic low‐osmolality contrast agent
for PCI. In the primary outcomes, CIN (>25% increase in serum creatinine level <72 h after
randomization) occurred in 14% in the NAC‐treated group and 20% in the placebo group, with
no significant differences; the MRI (measured as myocardial salvage index by MRI) was also
not statistically significant difference in both groups, so it is concluded that NAC not provide
an additional clinical benefit to placebo with respect to CIN and MRI. However, activated
oxygen protein products and oxidized low‐density lipoprotein were evaluated as oxidative
stress markers in blood plasma (in venous blood samples collected before, immediately after
PCI, and subsequently for up to 3 days) and found that the NAC‐treated group had a significant
reduction (20%) of these markers, while the placebo group had no significant differences. In
another study, patients with AMI that received NAC infusion (a total dose of 15 g/24 h),
combined with IV nitroglycerin and streptokinase, were well tolerated together with having
significantly lesser oxidative stress, a trend toward more rapid reperfusion and better preser‐
vation of left ventricular function compared to control group [82].
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3.3. Deferoxamine
It has been shown in I/R models of isolated perfused heart that during a period of ischemia
the amount of tissue available iron (Fe) increases in a time‐dependent manner. Fe is rapidly
mobilized through the perfusion fluid leading to very high Fe levels (up to 50‐fold compared
to pre‐ischemic values) in the first small volumes of coronary flow fractions (CFF), returning
to baseline over time. In addition, the levels of Fe in the CFFs correlated well with the loss of
cardiac function following global ischemia of varying duration [83]. Similarly, the Fe levels
increase up to 30‐fold in cardiac tissue during ischemia, in a time‐dependent manner, due to
acidification in ischemia because this effect contributes tremendously to the mobilization of
Fe from intracellular ferritin storage. After reperfusion, tissue Fe levels decrease, although it
is known that the superoxide anion contributes to the mobilization of Fe from ferritin [84–86].
Langendorff models with myocardial iron overload develop different functional, biochemical
and ultrastructural alterations as compared to control groups of myocardial I/R, which are
prevented by deferoxamine (DFO), an iron chelator [87], realizing the harmful tissue effect of
Fe high levels. The role of Fe in the postischemia MRI has been demonstrated in experimental
models by the use of iron chelators at the onset of reperfusion, improving cardiac function
relative to control group [88, 89]. Furthermore, a long‐term study conducted in randomly
selected men aged 42, 48, 54 and 60, who had no symptoms of coronary heart disease at entry,
showed that elevated levels of serum ferritin (stored Fe) was a strong risk factor for developing
AMI [90].
Physiologically, transition metals, such as iron, are mainly stored or complexed. However,
under certain pathological conditions, the nonchelated state iron levels are increased, thus
generating oxidative stress. Reduced iron (Fe2+) can react with hydrogen peroxide to generate
hydroxyl radical (•OH), a process known as Fenton reaction (Table 2A). At the same time,
oxidized iron (Fe3+) can react with superoxide anion to form again Fe2+ and oxygen (Table 2B).
The sum of the Fenton reaction and the superoxide‐mediated reduction of Fe3+ originates the
Haber–Weiss reaction (Table 2C), where hydroxyl radical is generated from superoxide anion
and hydrogen peroxide [24]. Thus, during myocardial I/R increase, the Fe2+ availability and
ROS levels that favor the formation of highly harmful and reactive hydroxyl radical through
these redox reactions, can significantly contribute to MRI. This allows considering the iron
overload during I/R as a pharmacological target for cardioprotection.
In addition, our interest is focused on the interaction between vitamin C and iron. Ascorbate
has pro‐oxidant effect because of reduction of Fe3+ to Fe2+ (Table 2D), which is substrate to
Fenton reaction leading to ROS production [92]. Under physiological conditions, in vivo studies
with vitamin C supplementation showed predominantly reduced levels in markers of
oxidative damage in DNA, lipids and proteins, even in the presence of iron. These results were
correlated with in vitro systems, such as isolated or cultured cells and biological fluids, where
the antioxidant role, or no effect of vitamin C, predominated over a pro‐oxidant role [91].
Considering that iron overload occurs in postischemia myocardial reperfusion, IV infusion of
high doses of vitamin C at the onset of reperfusion could generate a strong interaction with
iron, which not only decrease the concentration of ascorbate available in blood to counteract
the burst of oxidative stress, reducing its antioxidant effect, but also favor pro‐oxidant effects
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and ROS production. Thus, use of an iron chelator, as DFO, as adjuvant to antioxidant therapy
with vitamin C should be considered to reduce deleterious effects and maximize cardiopro‐
tection in patients with AMI being subjected to PCA. A experimental study in pigs showed
that the combined use of vitamin C (100 mg/kg) and DFO (60 mg/kg), administered as IV
infusion at the beginning, during and after reperfusion postischemia, had no difference in the
measured cardiac parameters compared to the control group, although it was observed a trend
toward reducing infarct size [94]. However, no markers of oxidative stress, apoptosis or other
biochemical parameter related to myocardial damage were measured. Another study in sheep
demonstrated that administration by IV infusion of vitamin C (1.5 g) and DFO (1 g) (in
combination but not separately), before reperfusion, significantly protected against the
development of ventricular arrhythmias induced by I/R, compared to control group [95].
Reaction Rate constant (M−1 s−1)
(A) Fe2 ++ H2O2 Fe3 ++ ⋅ OH + OH− 76
(B) O2⋅ −+ Fe3 + O2+ Fe2 + 1.9 × 106 –104
(C) O2⋅ −+ H2O2 O2+ ⋅ OH + OH− <2.3
(D) AscH−+ Fe3 + Asc ⋅ −+ Fe2 ++ H+ 102
H2O2, hydrogen peroxide; Fe2+, reduced iron; Fe3+, oxidized iron; •OH, Hydroxyl radical; OH‾, Hydroxyl anion; O2•‾,
Superoxide anion; O2, Molecular oxygen; AscH‾, Ascorbate; Asc•‾, Ascorbyl radical [91–93].
Table 2. Fenton (A), Haber–Weiss (C) and others redox reactions.
DFO has shown beneficial effects in experimental models of I/R. Isolated, perfused rabbit
hearts treated with DFO, during ischemia and reflow, demonstrated improved functional and
metabolic recovery of myocardium together a reduction in reperfusion‐induced oxygen free‐
radical generation, compared to control group [96]. In a canine model of I/R, DFO pretreatment
before ischemia, but not at the beginning of reperfusion, reduced significantly infarct size and
release of GSSG into the coronary sinus during early reflow, compared to control group [97].
Decrease in infarct size by early treatment with DFO was corroborated by another independent
study in canine model of I/R [98]. Regarding clinical trials, patients undergoing coronary artery
bypass grafting, that received an IV infusion of DFO for 8 hours, prevented the increase in
oxidative stress markers and improving ventricular functional parameters after surgery,
compared to control group [99]. Other clinical trial in patients with ST‐elevation MI subjected
to primary percutaneous coronary intervention (PPCI) showed that administration of IV bolus
of DFO (500 mg) immediately before surgery, followed by a 12‐h infusion (50 mg/kg),
significantly reduced in plasma F2‐isoprostane levels, with no difference in infarct size, after
PPCI compared to placebo group [100].
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4. Conclusion and perspectives
In this chapter, we have reviewed the molecular processes involved in the pathophysiology of
myocardial damage by postischemia reperfusion, emphasizing the central role of oxidative
stress as the key mediator of this damage. Accordingly, increased ROS production can give
rise to the occurrence of events ranging from inflammation, damage to biomolecules and
metabolic cell impairment to even cell death. From this paradigm, a novel antioxidant therapy
is proposed as cardioprotective action in patients with AMI subject to PCA. This treatment
considers the use of vitamin C (sodium ascorbate) in high doses administered intravenously,
combined with NAC and DFO prior to surgery so as to optimize and enhance the beneficial
effects and reduce the harmful effects on myocardium occurring in this setting (Figure 5).
However, the results from different experimental models are controversial and more studies
are still lacking. On this line, it is important to note that MRI is an unsolved problem in the
clinical practice. Different strategies to prevent this damage during surgery for revasculariza‐
tion in patients with AMI have been tried without conclusive results, and we expect that our
proposal can contribute as an effective, low risk and economic alternative in the near future.
Figure 5. Diagram of the proposed combined antioxidant therapy for patients with AMI subject to PCA, which consid‐
ers the use of: (i) ascorbate (AscH−) in high doses to compete with nitric oxide (•NO) by superoxide anion (O2•‾); (ii)
deferoxamine (DFO) to counteract reduced iron (Fe2+) overload and thus prevent the Fenton reaction and interaction
with AscH−; (iii) N‐acetyl cysteine (NAC) as reduced glutathione (GSH) donor to reinforce the antioxidant defense sys‐
tem and mitigate its interaction with dehydroascorbic acid (Asc). In this way, it counteracts directly and indirectly the
hydroxyl radical (•OH), which is the main mediator of myocardial damage by oxidative stress during reperfusion.
H2O2, hydrogen peroxide; GSSG, oxidized glutathione; ONOO−, Peroxynitrite; Fe3+, oxidized iron.
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mPTP mitochondrial permeability transition pore
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NOX NADPH oxidase
Nrf2 nuclear factor‐erythroid 2‐related factor 2
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ROS reactive oxygen species
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TNFα tumor necrosis factor alpha
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